In Dec, 2021, Shanghai HeartCare Medical Technology Corporation Limited received approval from the National Medical Products Administration (CFDA) for Fulltrap Embolic Protection System and Easywire Neuro Micro Guidewire, which marks another milestone towards the target to provide one-stop solution and become the industry leader for stroke therapeutics and prevention, with our full-set pipeline of products for acute ischemic stroke ,neurovascular stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment, and interventional vascular access.